94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1564561
This article is part of the Research Topic Advances in Immunosuppressive Microenvironment Remodeling and Targeted Drug Intervention in Pancreatic Cancer View all articles
Global trends in resistance studies of gemcitabine and pancreatic cancer: a bibliometric and visual analysis from 2010 to 2024
Provisionally accepted- 1 Northeast Yunnan Regional Central Hospital, Zhaotong, Yunnan, China
- 2 College of Life Sciences, Shaanxi Normal University, Xi'an, China 710119, Xi'an, China
- 3 dali, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Dali University, Dali 671000, China, China
Introduction: Pancreatic adenocarcinoma (PC) represents a prevalent and highly aggressive malignancy within the digestive system, characterized by an exceedingly poor prognosis and a dismal 5-year survival rate of below 7%. Gemcitabine (GEM) remains the cornerstone chemotherapeutic agent in the management of PC; however, the growing challenge of GEM chemoresistance, which undermines treatment efficacy, represents a significant obstacle in clinical practice. To date, no comprehensive bibliometric analysis has been undertaken to systematically explore studies on GEM resistance in the context of PC. This study aims to deliver a thorough evaluation of the research hotspots pertaining to GEM resistance in PCs. Method: A systematic search was conducted for articles published from January 1, 2010, to December 15, 2024, focusing on resistance studies of GEM in PC. Bibliometric analysis and visualization were performed utilizing VOSviewer and CiteSpace tools, applied to literature data extracted from the Web of Science Core Collection (WoSCC). Results: Between 2010 and 2024, a total of 2689 papers were published across 472 institutions in 74 countries, reflecting a consistent upward trajectory in annual publication output. China and Fudan University emerged as the leading contributors to the research output on this topic, representing the most prolific country and institution, respectively. Giovannetti, Elisa, and Yu, Xianjun are the most prolific scholars in this field. Cancer Research stands out as the most cited and impactful journal, while research on the tumor microenvironment, targeted therapy, and circular RNA has emerged as a key focus area in recent years.This study provides a systematic and comprehensive overview of the literature on GEM resistance in PC over the past 15 years. This analysis offers scholars critical insights into the field from a bibliometric perspective, potentially informing future studies on the development of chemotherapeutic treatments for PC. Table 7. Highly co-cited literature (top 10).
Keywords: Pancreatic Cancer, gemcitabine, Drug Resistance, Citespace, VOSviewer, bibliometric analysis
Received: 21 Jan 2025; Accepted: 31 Mar 2025.
Copyright: © 2025 Gu, Huang, Zhao, Zhang, Zhang and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wei Xiong, dali, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Dali University, Dali 671000, China, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.